Last reviewed · How we verify

Paricalcitol, atorvastatin — Competitive Intelligence Brief

Paricalcitol, atorvastatin (Paricalcitol, atorvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D receptor activator + HMG-CoA reductase inhibitor (statin). Area: Nephrology / Cardiovascular.

phase 3 Vitamin D receptor activator + HMG-CoA reductase inhibitor (statin) Vitamin D receptor (VDR) + HMG-CoA reductase Nephrology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Paricalcitol, atorvastatin (Paricalcitol, atorvastatin) — Ricardo Mouzo Mirco. This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paricalcitol, atorvastatin TARGET Paricalcitol, atorvastatin Ricardo Mouzo Mirco phase 3 Vitamin D receptor activator + HMG-CoA reductase inhibitor (statin) Vitamin D receptor (VDR) + HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D receptor activator + HMG-CoA reductase inhibitor (statin) class)

  1. Ricardo Mouzo Mirco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paricalcitol, atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/paricalcitol-atorvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: